Pediococcus acidilactici probiotic tolerance to heat and acidity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional probiotics like Bifidobacterium and Lactobacillus are sensitive to air exposure, elevated temperatures, and stomach acids, limiting their effectiveness in treating inflammatory conditions.
Innovation Solution
Administration of Pediococcus acidilactici probiotic, specifically strain NRRL B-50517, which is tolerant to elevated temperatures, low pH values, and aerobic and anaerobic conditions, increases anti-inflammatory M2 macrophage cells, IL-10 production, and decreases IL-6 and IL-23 levels, effectively treating various inflammatory diseases and conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional probiotics (Bifidobacterium and Lactobacillus) are used, then probiotic health benefits are provided, but the probiotics are sensitive to air exposure, elevated temperatures, and stomach acids, limiting their effectiveness
Solution Approach 1:
The patent changes the species parameter from conventional probiotics (Bifidobacterium and Lactobacillus) to Pediococcus acidilactici, which has fundamentally different tolerance parameters. This new probiotic strain can withstand air exposure, elevated temperatures (including autoclaving at 121°C), and stomach acids, directly resolving the sensitivity issue while maintaining probiotic effectiveness
Solution Approach 2:
The patent utilizes a probiotic strain that can survive harsh processing conditions and storage environments, eliminating the need for expensive specialized packaging and cold chain logistics required by conventional probiotics. The Pediococcus acidilactici can be stored at room temperature and survives standard sterilization processes
2Reliability
If Pediococcus acidilactici probiotic is administered, then anti-inflammatory responses are enhanced and pro-inflammatory cytokines are reduced, but the specific mechanism and dosage optimization require further investigation
Solution Approach 1:
The patent identifies and optimizes the dosage parameter of Pediococcus acidilactici administration, establishing effective dosage ranges that achieve anti-inflammatory effects. By determining optimal dosing parameters, the patent simplifies the treatment protocol while maintaining therapeutic effectiveness, reducing the complexity of treatment implementation
Data Source
AI summary
The present invention provides a method of treating a disease or condition characterized by inflammation in a subject in need thereof, comprising administering to the subject an effective amount of a Pediococcus acidilactici probiotic. Compositions of Pediococcus acidilactici probiotic are also provided.